The Latest Cardiac and Vascular News
PRINCETON, N.J., May 1, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated…
First fully absorbable, sutureless closure system designed for large-bore procedures aims to improve procedural efficiency and patient outcomes in structural heart interventions GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced European CE mark approval of the PerQseal® Elite vascular closure system, a […]
TEL AVIV, Israel, April 8, 2025 /PRNewswire/ — CardioVia, an innovative medical device company specializing in advanced cardiac care solutions, announced today that it has received U.S. Food and Drug Administration (FDA) clearance for its ViaOne system. This breakthrough device is…
Brainomix 360 unlocks expert-level insights from universally available non-contrast CT scans, helping stroke networks expand access to life-changing treatments OXFORD, England and CHICAGO, April 8, 2025 /PRNewswire/ — Brainomix, a global leader in AI-powered stroke imaging, has announced…
Patented SelectFlex™ Technology allows operators to achieve the ideal balance of trackability and support on demand to navigate complex neurovasculature System enables biaxial approach, regardless of access site, to eliminate complexity and cost of conventional configurations FREMONT,…
Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial TEWKSBURY, Mass., Dec. 20, 2024 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it has achieved CE certification for the Corvia®…
Company expands clinical program beyond 70 patients already treated in South America FIH and Feasibility Studies. FDA acknowledged potential benefits of the Supira System by granting the company a review pathway under the Breakthrough Device Program. Results from EFS will be used to support submission to FDA for Supira’s pivotal […]
Company prepares to support clinical trial in the United States NEW BRUNSWICK, N.J., Nov. 12, 2024 /PRNewswire/ — Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, today announced that the U.S. Food & Drug Administration (FDA) has…
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) — R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that the U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of its next generation drug eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD.
First and Only Dual Monorail Microcatheter System Purpose-Built for Complex Coronary and Peripheral Interventions SAN JOSE, Calif., Oct. 25, 2024 /PRNewswire/ — Vantis Vascular, Inc., a pioneering medical technology company founded by physicians with a passion to revolutionize vascular…
